Oxford BioMedica is a prominent gene and cell therapy company that is devoted to finding cures for critical ailments. The company has pioneered a dominant lentiviral vector delivery platform called LentiVector®, through which it creates in vivo and ex-vivo treatments in-house and with partners. With a remarkable portfolio of gene and cell therapy products specializing in oncology, ophthalmology, and CNS disorders, the company has established itself as a significant player in this field.
Oxford Biomedica's ticker is OXB
The company's shares trade on the LSE stock exchange
They are based in Oxford, England
There are 201-500 employees working at Oxford Biomedica
It is oxb.com
Oxford Biomedica is in the Healthcare sector
Oxford Biomedica is in the Biotechnology industry
The following five companies are Oxford Biomedica's industry peers: